- Pfizer Inc (NYSE: PFE) has paused enrollment in a pivotal trial of its anti-BCMA bispecific antibody after seeing three cases of peripheral neuropathy in an earlier-stage study.
- In February, Pfizer took its BCMA bispecific elranatamab, also known as PF-06863135, into a pivotal Phase 2 study on the strength of the 80% overall response rate it saw in 20 patients treated in Phase 1.
- The pause was triggered by the discovery of three cases of peripheral neuropathy in the Phase 1 trial.
- Pfizer disclosed the BCMA setback as part of a first-quarter update that also covered the status of its DMD gene therapy fordadistrogene movaparvovec, formerly known as PF-06939926.
- Dosing in a phase 3 trial of the gene therapy began at ex-U.S. sites late last year.
- However, Pfizer is yet to get the green light to start dosing at U.S. sites and does not expect to do so in the first half of 2021.
- The first-quarter update also brought news of the discontinuation of two projects. Pfizer is stopping work on IL-10 drug Dekavil in ulcerative colitis, and JAK3/TEC inhibitor ritlecitinib in rheumatoid arthritis.
- Price Action: PFE shares are up 0.32% at $39.70 during the market session on the last check Tuesday.
Nio Says NOP Autonomous Driving System ‘Less Aggressive’ Than Rivals As EV Maker ‘Prioritizes Safety’
Electric vehicle maker Nio Inc (NYSE: NIO) suggested on Wednesday the autonomous driving system on its ET7 electric sedan is deliberately "less aggressive" than rivals to prioritize safety.
